- Stocks
- Healthcare
- NASDAQ: RGEN

Price (delayed)

$190.14

Market cap

$10.44B

P/E Ratio

127.61

Dividend/share

N/A

EPS

$1.49

Enterprise value

$10.01B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in

RGEN's gross profit has soared by 54% YoY and by 19% QoQ

The revenue has soared by 52% YoY and by 18% from the previous quarter

RGEN's quick ratio has dropped by 82% year-on-year but it is up by 3.6% since the previous quarter

The debt has grown by 5% YoY

What are the main financial stats of RGEN

Market
Valuations
Earnings

Shares outstanding

54.9M

Market cap

$10.44B

Enterprise value

$10.01B

Price to earnings (P/E)

127.61

Price to book (P/B)

6.69

Price to sales (P/S)

24.07

EV/EBIT

106.57

EV/EBITDA

81.35

EV/Sales

23.11

Revenue

$433.01M

EBIT

$93.91M

EBITDA

$123.03M

Free cash flow

$31.98M

Per share
Balance sheet
Liquidity

EPS

$1.49

Free cash flow per share

$0.58

Book value per share

$28.41

Revenue per share

$7.9

TBVPS

$18.76

Total assets

$1.93B

Total liabilities

$371.11M

Debt

$279.89M

Equity

$1.56B

Working capital

$613.01M

Debt to equity

0.18

Current ratio

2.96

Quick ratio

2.56

Net debt/EBITDA

-3.51

Margins
Efficiency
Dividend

EBITDA margin

28.4%

Gross margin

57.4%

Net margin

18.4%

Operating margin

21.8%

Return on assets

4.7%

Return on equity

6%

Return on invested capital

26.9%

Return on capital employed

5.8%

Return on sales

21.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Repligen stock price performed over time

Intraday

0.26%

1 week

2.1%

1 month

10.57%

1 year

62.87%

YTD

-0.78%

QTD

-2.2%

How have Repligen's revenue and profit performed over time

Revenue

$433.01M

Gross profit

$248.61M

Operating income

$94.3M

Net income

$79.56M

Gross margin

57.4%

Net margin

18.4%

The operating income has soared by 156% YoY and by 35% from the previous quarter

The net margin has soared by 127% YoY and by 12% from the previous quarter

The operating margin has soared by 69% YoY and by 14% from the previous quarter

RGEN's gross profit has soared by 54% YoY and by 19% QoQ

What is Repligen's growth rate over time

What is Repligen stock price valuation

P/E

127.61

P/B

6.69

P/S

24.07

EV/EBIT

106.57

EV/EBITDA

81.35

EV/Sales

23.11

RGEN's EPS is up by 31% since the previous quarter

The stock's P/E is 26% below its last 4 quarters average of 172.4

Repligen's equity has increased by 45% YoY

The P/B is 34% more than the 5-year quarterly average of 5.0

RGEN's P/S is 60% above its 5-year quarterly average of 15.0

The revenue has soared by 52% YoY and by 18% from the previous quarter

How efficient is Repligen business performance

The return on equity has surged by 161% year-on-year and by 20% since the previous quarter

RGEN's ROA has soared by 161% year-on-year and by 24% since the previous quarter

The ROIC has soared by 147% YoY and by 45% from the previous quarter

RGEN's return on sales has surged by 68% year-on-year and by 11% since the previous quarter

What is RGEN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RGEN.

How did Repligen financials performed over time

RGEN's quick ratio has dropped by 82% year-on-year but it is up by 3.6% since the previous quarter

Repligen's current ratio has shrunk by 81% YoY but it has increased by 4.6% QoQ

The debt is 82% less than the equity

Repligen's equity has increased by 45% YoY

Repligen's debt to equity has decreased by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.